II-VI, Inc. (IIVI) PT Raised to $45 at Needham & Company Following 4Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
II-VI (IIVI) 3D Sensing Comments a Near-Term Positive for Lumentum (LITE) - Stifel
August 7, 2017 1:23 PM EDTStifel analyst Patrick Newton views II-VI's (NASDAQ: IIVI) results as incrementally positive for Lumentum Holdings (NASDAQ: LITE), and to a lesser extent Finisar (NASDAQ: FNSR), in the near-term given constructive commentary on the 3D sensing market opportunity, datacom strength,... More
Pre-Open Movers 08/07: (MYOK) (NXTM) (COL) Higher; (ZYNE) (GEMP) (IPI) Lower (more...)
August 7, 2017 9:33 AM EDTToday's Pre-Open Stock Movers
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) 55.9% LOWER; announced top-line results from its double-blind placebo controlled Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 (cannabidiol [CBD] gel) in adult epilepsy patients with focal seizures. ZYN002 did not demonstrate a statistically significant reduction of focal seizures during the treatment period compared to the baseline period for either the high or low dose cohorts compared to placebo.
Gemphire Therapeutics Inc. (NASDAQ: GEMP) 38.1% LOWER;... More
II-VI, Inc. (IIVI) Tops Q4 EPS by 15c
August 7, 2017 6:56 AM EDTII-VI, Inc. (NASDAQ: IIVI) reported Q4 EPS of $0.50, $0.15 better than the analyst estimate of $0.35. Revenue for the quarter came in at $273.7 million versus the consensus estimate of $249.9 million.
GUIDANCE:
II-VI, Inc. sees Q1 2018 EPS of $0.30-$0.34, versus the consensus of... More
II-VI, Inc. (IIVI) Buys Kaiam's 6-inch Wafer Fabrication Facility in the U.K.
August 7, 2017 6:51 AM EDTIIVI Incorporated (NASDAQ: IIVI), a leader in engineered materials and optoelectronic components, today announced its acquisition of Kaiam Laser Limited, a 6-inch wafer fabrication facility in Newton Aycliffe in the United Kingdom. The purchase price of the transaction was $80.0 million, and paid for from the Companys cash reserves. The acquisition is expected to be breakeven at the EBITDA level within 12 months.
The 300,000 square foot facility hosts a state of the art 100,000 square foot clean room designed for high volume... More
